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Abstract
West Nile virus (WNV) is a mosquito-borne flavivirus that infects humans and other mammals. In some cases WNV causes
severe neurological disease. During recent years, outbreaks of WNV are increasing in worldwide distribution and novel
genetic variants of the virus have been detected. Although a substantial amount of data exists on WNV infections in rodent
models, little is known about early events during WNV infection in primates, including humans. To gain a deeper
understanding of this process, we performed experimental infections of rhesus macaques and common marmosets with a
virulent European WNV strain (WNV-Ita09) and monitored virological, hematological, and biochemical parameters. WNV-
Ita09 productively infected both monkey species, with higher replication and wider tissue distribution in common
marmosets compared to rhesus macaques. The animals in this study however, did not develop clinical signs of WNV disease,
nor showed substantial deviations in clinical laboratory parameters. In both species, the virus induced a rapid
CD56dimCD16bright natural killer response, followed by IgM and IgG antibody responses. The results of this study show that
healthy rhesus macaques and common marmosets are promising animal models to study WNV-Ita09 infection. Both models
may be particularly of use to evaluate potential vaccine candidates or to investigate WNV pathogenesis.
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Introduction
West Nile virus (WNV) is a mosquito-borne RNA virus
within the Flavivirus genus. Mosquitos of the genus Culex are
the most important insect vectors, but the virus can also be
transmitted by a wide variety of mosquitos from other genera
[1]. The enzootic viral lifecycle is between mosquitos and bird
species, but transmission can also occur to other hosts,
including horses and humans. In humans, the majority of
infections (80%) are asymptomatic, and approximately 20% of
the infected individuals develop a febrile syndrome, charac-
terized by weakness, myalgia, and fatigue. In less than 1% of
WNV-infected patients, illness progresses to a sometimes fatal,
neuro-invasive form that results in meningitis, encephalitis, or
paralysis. The elderly and immunocompromised are at
substantially higher risk for severe WNV disease [2] compared
to immunocompentent individuals.
WNV was first isolated in Uganda in 1937 [3], and was
originally endemic in Africa, parts of Asia, the Middle East, the
southeastern Mediterranean countries, and Australia where a
specific subtype of WNV, Kunjin virus, was found [4].
In 1999, WNV was first isolated in New York, and since then
has rapidly spread over the American continent. In Europe, the
virus sporadically caused infections in horses, but in 1996 an
outbreak in Romania caused several human cases of encephalitis.
Since then, human fatalities have been reported in Central and
Eastern Europe, Greece, and Italy. In addition, surveillance
programs have reported equine infections in other Mediterranean
countries [5–7], suggesting the spread of WNV across the
European continent.
Seven phylogenetic WNV lineages have been reported, of which
lineages 1 and 2 are the most widely distributed [8]. Until 2004,
viruses belonging to lineage 1 caused all WNV infections in
Europe, but since then lineage 2 viruses have caused outbreaks in
Central and Eastern European countries. In 2010, a lineage 2
virus caused a large epidemic in Greece with 262 human cases [9].
The recent outbreaks of WNV disease in humans [4,10,11]
highlight an immediate need for a WNV vaccine for human use.
Several vaccine candidates for WNV have been evaluated in mice
[12,13], but data obtained from this rodent model have limited
prognostic value for the efficacy in humans because of basic
differences in the immune system [14–16]. Equally, viral
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pathogenesis and persistence of WNV infection has been studied
in mice and hamsters [17–22], although the relevance to human
disease is not entirely clear. Indeed, WNV infection of inbred
rodents is characterized by a rapid development of neurological
symptoms and a high mortality rate, features that do not reflect
human infection. Non-human primates, with an immune system
that is more similar to humans, may provide a more suitable
animal model for the development and evaluation of vaccines for
use in humans and to study pathogenesis.
Only one vaccine candidate is currently being evaluated in
humans [23–25]. This candidate is a live attenuated chimeric
vaccine, constructed from yellow fever and WNV (pre) membrane
genes, making this vaccine less suitable for the population with
high risk of developing WNV disease.
Several WNV infection studies in non-human primates have
been published. In the 1950s, studies were performed in Old and
New World monkey species [26,27], and more recently, Pogodina
et al. [28] investigated viral persistence after subcutaneous and
intracranial WNV inoculation in rhesus macaques. However,
these studies were performed with lineage 1 and 2 WNV strains
that pre-dated the recent epidemics that began in the 1990’s. More
recently, Ratterree et al. [29] performed experimental infections of
rhesus macaques with the pathogenic WNV NY99 strain, and
showed that macaques developed an infection course that was
similar to that seen in humans. These results were largely
confirmed in a study by Wolf et al. [30], who experimentally
infected baboons, another Old World primate, with North
American lineage 1 isolates of the 2002–2003 epidemics, and that
are closely related to the NY99 strain. The NY99 strain has also
been used for pre-clinical testing of WNV vaccines in macaques
[23,24,31–33].
Pogodina et al. revealed strain-specific variations in the clinical
course of infection in macaques [28]. WNV-Ita09 is a strain from
Italy, which was isolated during an outbreak in northern Italy in
2008–2009 that caused several human cases of neuro-invasive
disease with severe symptoms [34,35]. WNV-Ita09 and NY99
belong to the same lineage (1a) but to different clades (2 and clade
4, respectively) [8]. Despite genetic similarity of 99.5%, they may
have different biological and immunopathological properties. In
vivo characterization of the European strain WNV-Ita09 is
therefore of direct interest to future WNV vaccine development.
As most human infections with WNV are clinically inapparent,
little is known regarding the early events of WNV infection. Here,
we have developed an infection- model with the WNV-Ita09 strain
in rhesus macaques and common marmosets to investigate its
replication and tissue distribution. We aimed to investigate the
early events using animal species with immune systems that are
similar to that of humans. Although the rhesus macaque is an
established model for evaluating candidate WNV vaccines, their
body-size requires specialized housing and large amounts of test
compounds. The development of a smaller and less expensive non-
human primate-model, such as the common marmoset, would
therefore be of great value. WNV studies using common marmoset
have not yet been published, but this species holds promise as it
has been proven a suitable animal model for infection with related
flaviviruses, such as GBV-B and dengue virus [36–40]. Our studies
with WNV-Ita09 revealed productive infection of both monkey
species, with higher WNV RNA production and wider tissue
distribution in marmosets compared to rhesus macaques.
Methods
Ethics statement
The rhesus macaques (Macaca mulatta) and common marmosets
(Callithrix jacchus) used in this study were captive bred for research
purposes and were socially housed at the Biomedical Primate
Research Centre (BPRC) in Rijswijk, The Netherlands. BPRC
facilities comply with Dutch law on animal experiments (Wet op
de Dierproeven, and its adaptations as published in the
Staatscourant), the European Council Directive 86/609/EEC, as
well as with the ‘Standard for humane care and use of Laboratory
Animals by Foreign institutions’ identification number A5539-01,
provided by the Department of Health and Human Services of the
United States of America’s National Institutes of Health (NIH).
The animals were pair-housed in a BSL3-facility with spacious
cages and were provided with commercial food pellets supple-
mented with appropriate treats. Drinking water was provided ad
libitum. Enrichment was provided in the form of pieces of wood,
mirrors, food puzzles, a variety of food and other home made or
commercially available enrichment products. Animals were
monitored daily for health and discomfort.
All procedures were approved by the Institutional Animal Care
and Use Committee (BPRC Dier Experimenten Commissie,
BPRC-DEC; DEC advice #691). The qualification of the
members of this committee, including their independence from a
research institute, is requested in the Wet op de Dierproeven
(1996). At the BPRC all animal handling is performed within the
Department of Animal Science (ASD) according to Dutch law. A
large experienced staff is available including full time veterinarians
and a pathologist. The ASD is regularly inspected by the
responsible authority (Voedsel en Waren Autoriteit, VWA) and
an independent Animal Welfare Officer. All steps were taken to
ameliorate the welfare and to avoid any suffering of the animals.
The experimental procedures require anesthesia (surgical insertion
of temperature probe) or sedation (intradermal injection of virus,
blood sampling). These were performed using ketamine and
cepetor (macaques), or Alfaxan and cepetor (marmosets). Monkeys
selected for euthanasia were first deeply sedated with ketamine/
alfaxan, and subsequently euthanized by intracardiac injection of
overdoses pentobarbital.
The Council of the Association for Assessment and Accredita-
tion of Laboratory Animal Care (AAALAC International) has
Author Summary
West Nile virus (WNV) is a mosquito-borne virus that can
infect mammals, including humans. Most infected humans
do not develop disease, but in about 20% of cases humans
develop WNV-related disease symptoms, varying in sever-
ity from fever to a sometimes life-threatening neuro-
invasive disease. The number of WNV infections in Europe
has increased in recent years and is caused by viruses that
are genetically different from the viruses that caused the
WNV epidemic in North America. In this study, we have
experimentally infected two different monkey species,
rhesus macaques and common marmosets, with the
European WNV isolate Ita09 to evaluate the early events
after infection and the onset of the disease. Both species
were equally susceptible to infection with WNV-Ita09, but
differences between species were observed. Compared to
rhesus macaques, common marmosets had higher virus
loads in blood, and presented a wider distribution of the
virus in various organs. Based on the analysis of virological,
immunological, biochemical and hematological parame-
ters, we conclude that rhesus macaques as well as
common marmosets are potentially useful animal models
to evaluate vaccine candidates or to investigate WNV
pathogenesis.
WNV Infection in Rhesus and Marmosets
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awarded full accreditation to the BPRC. Thus, the BPRC is fully
compliant with international demands on animal studies and
welfare as set out by the European Convention for the Protection
of Vertebrate Animals used for Experimental and other Scientific
Purposes, Council of Europe (ETS 123 including the revised
Appendix A), Dutch implementing legislation and the Guide for
Care and Use of Laboratory Animals.
Animals
Four common marmosets (Callithrix jacchus) and four rhesus
macaques (Macaca mulatta) were used in this study. All monkeys
used in this study were adult animals, ranging in age from 3–4
years old (marmosets), and 8–11 years old (macaques). All animals
were purpose-bred and housed at the Biomedical Primate
Research Centre (BPRC). The animals were in good physical
health with normal baseline biochemical and hematological
values. At the start of the study, the animals tested negative for
antibodies to WNV. The animals were pair-housed in a BSL3-
facility with spacious cages and were provided with commercial
food pellets supplemented with appropriate treats. Drinking water
was provided ad libitum. The experiments were performed in
accordance with Dutch law and international guidelines for non-
human primates in biomedical research, and were approved by
the authorized Institutional Animal Care and Use Committee
(BPRC-DEC).
Experimental infections and post-exposure follow-up
At day 0, the animals were intradermally inoculated in the
upper back with 100 ml of WNV lineage 1a strain Ita09 [35].
Rhesus macaques received 26105 TCID50, a dose that has been
described to be infective in rhesus macaques using the NY99 strain
[29,31]. The smaller sized common marmosets received 16105
TCID50 per animal. Virus titration was performed using Vero E6
cells [35]. After WNV infection, the animals were daily observed
for general condition, appetite and stool, until the end of the study.
Blood was collected using standard aseptic methods from the
femoral vein at time points indicated in Figure 1.
A wide range of parameters was analyzed including body
temperature and standard hematology and biochemistry. In
addition, viral load was quantified in EDTA-plasma, urine and
post mortem tissue samples. Flow cytometry was performed to assess
changes in a wide range of cell populations in peripheral blood.
Body temperature
Rectal body temperature was measured at time points of
sedation using a regular body thermometer. In addition, body
temperature of the animals was continuously recorded using DST
Micro-T data loggers (UNO Roestvrijstaal BV, Zevenaar, The
Netherlands). Fourteen days prior to WNV infection, the
thermometer probes were implanted in the abdominal cavity of
the animal, and programmed to assess the body temperature every
5 minutes. At euthanasia, the probes were recovered and the
collected data were analyzed.
Urine collection
Pooled urine from pair-housed animals was collected using a
tray on the bottom of the cage, and was stored at 280uC until
analysis.
Biochemistry and hematology analysis
A panel of hematological parameters i.e. white blood cell count
(WBC), red blood cell count (RBC), hemoglobin, hematocrit,
mean cellular volume (MCV), mean corpuscular hemoglobin
(MCH), platelets, neutrophils, lymphocytes, monocytes, eosino-
phils, and basophils, were analyzed in peripheral blood using a
Sysmex XT-2000iV Automated Hematology Analyzer (Sysmex
Nederland B.V., Etten-Leur, The Netherlands). Biochemical
analysis, i.e. creatinine, urea, bilirubin, gamma-glutamyltransfer-
ase (GGT), aspartate aminotransferase (AST), alanine amino-
transferase (ALT), alkaline phosphatase, lactate dehydrogenase
(LDH), iron, albumin, cholesterol, and glucose was assessed using
a COBAS Integra 400 plus system (Roche Diagnostics Nederland
B.V., Almere, The Netherlands).
Flow cytometry analysis
To assess changes in lymphocyte subset composition during
WNV infection, cells from EDTA-treated blood were stained with
seven different antibody combinations, [41] (see: supplementary
Table S1). All antibodies have been tested for cross-reactivity with
either rhesus macaque or common marmoset cells, and are listed
by the NIH Nonhuman Primate Reagent Resource (http://www.
nhpreagents.org/NHP/reagentlist.aspx). Immunofluorescence
was measured using the FACS Aria (Becton Dickinson BV,
Breda, The Netherlands), and data were analyzed with FlowJo
software, version 9.6.4 (Tree Star, Stanford University, USA).
Necropsy
All monkeys were euthanized at designated time points by
infusion of pentobarbital (Apharma, Duiven, The Netherlands),
and full necropsy was performed. Samples were collected from the
following tissues: CNS: cerebellum, hippocampus, brain stem,
parietal cortex, and spinal cord (cervical, thoracic, lumbar); oral
mucosa, tongue, tonsil, submandibular gland, thyroid gland, bone
marrow, esophagus, stomach fundus, pancreas, jejunum, duode-
num, ileum, colon, lung, spleen, left and right kidneys, adrenal
gland, thymus, inguinal lymph nodes (ing LN), axillary lymph
nodes (ax LN), mesenteric lymph nodes (mes LN), heart, urinary
bladder, testis or uterus and ovary, skeletal muscle, skin, sciatic
nerve, and aorta. All samples were snap frozen for WNV-RNA
detection.
Antibody response
To assess WNV-specific antibodies in plasma, an anti-WNV-E
antigen ELISA was performed. Briefly, 96-well microtiter plates
were coated overnight with 400 ng of the ectodomain of the
WNV-E-protein (NY99 strain), which was expressed in E. coli and
purified as described previously [42]. Diluted EDTA plasma
samples (1:50) were incubated with the coated antigen for 2 hrs,
followed by 1 hr incubation of either goat-anti-human IgG
(Thermo Fisher Scientific, Schwerte, Germany) or goat-anti-
human IgM (www.antikoerper-online.de, Germany), both HRP-
conjugated. After washing, TMB-substrate (BioLegend, Fell,
Germany) was added to the wells and the plate was incubated
for 30 min at RT in darkness. Then, 1 M H2SO4 was added to
stop the reaction, and plates were measured at 450 nm and
520 nm (reference wavelength) in an ELISA Reader (Infiniti
M200, Tecan, The Netherlands).
Virus detection in blood, urine and tissue
Virus loads in blood were tested with quantitative real-time
PCR assay. In addition, a diagnostic nested PCR assay was
performed on tissue samples. From each organ collected during
necropsy, two or three different tissue pieces were taken for total
RNA isolation, and each sample was independently tested for the
presence of WNV RNA. Virus loads were determined by real-time
quantitative RT-PCR, as described by Lanciotti et al. [43]. The
WNV Infection in Rhesus and Marmosets
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lower detection limit of the qRT-PCR was 20 viral RNA copies
per reaction. Viral RNA was isolated from plasma and urine
samples using a QIAamp Viral RNA Mini kit (Qiagen Benelux
BV, Venlo, The Netherlands) following the manufacturer’s
instructions.
Total RNA was extracted from frozen tissue samples using the
RNeasy Plus Mini kit (Qiagen). RNA was reverse-transcribed to
cDNA using a Transcriptor First Strand cDNA Synthesis kit
(Roche Diagnostics BV, Almere, The Netherlands). WNV was
detected using a nested diagnostic PCR assay with an outer primer
set WNV-F-out (GAGGACATCTGGTGTGGCAG) and WNV-
R-out (ACCTACAGCTTCAGTCAGGC), in combination with
an inner set WNV-F-in (TGGTTGAGGACACAGTACTG) and
WNV-R-in (TCGCAGACTGCACTCTCCGC). In this test a
345 bp fragment of WNV lineage 1 viruses was amplified. The
outer amplification reaction was performed in a 50 ml volume
using 10 ml of cDNA, 2,5 units TrueStart Hot Start Taq DNA
polymerase (Fermentas GMBH, St. Leon-Rot, Germany), 5 ml
106TrueStart PCR buffer, 1 pmol of each primer, 3 mMMgCl2,
and 200 mM of each dNTP. In the second amplification reaction,
2 ml of the PCR product of the outer PCR was used as template,
and inner PCR conditions were identical to those for the outer
PCR. Cycling conditions for both reactions were 95uC for 20 sec,
55uC for 20 sec, and 72uC for 40 sec.
Virus isolation from plasma
Plasma samples from days 0, 2, 6 and 14 post-infection were
used for virus titration on Vero cells. Plasma samples were tested
in triplicate in 96-well culture plates that were seeded with Vero
cells to 80% confluence. The plasma samples were tested at 2-fold
dilutions, starting with a 1:25 diluted sample. WNV titers were
calculated using the method of Reed and Muench [44].
Figure 1. Time schedule. On each time line, blue arrows indicate the time-points of the implantation of the data loggers for temperature
registration, the intradermal WNV infection, and euthanasia. Red arrows indicate the bleeding time-points in the follow-up period. The numbers on
the time line represent the days post-infection. Names of the animals are depicted with the ‘‘R’’-animals being rhesus macaques and the ‘‘M’’-animals
being common marmosets.
doi:10.1371/journal.pntd.0002797.g001
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Statistical analysis
Statistical analysis was performed using Graph Pad Prism
version 6.0b.
Difference in total virus production, defined as area under the
curve, was analyzed using two-tailed unpaired t-test. A significant
difference was defined as p,0.05.
Statistical analysis of the hematology and biochemistry data was
performed as follows: the mean value of the two rhesus macaques
measured at time point x was compared with the mean value of
the two animals at time point 0 using a 2-way ANOVA test.
Significant difference was defined as p,0.05.
Results
WNV replication in rhesus macaques and common
marmosets
The WNV infection study was divided into two experiments.
The first experiment was performed to determine the kinetics
of viral infection in the two monkey species. In addition, a set
of hematological and biochemical parameters was monitored
in two rhesus macaques and two common marmosets. Post
mortem organ examination was performed at two weeks after
infection. In the second experiment we determined the virus
distribution in various tissues at the peak of WNV infection
(Figure 1).
Intradermal inoculation with the WNV strain Ita09 was
successful in both monkey species, as was reflected by the viremia
that was detectable as early as one day after inoculation (Figures 2A
and B; dark blue area). Marmosets showed a longer viremic period
compared to the rhesus macaques (8 to 10 days versus 4 to 5 days).
Marmosets also developed higher peak virus loads than rhesus
macaques 1.36106 and 9.96104 copies of WNV RNA/ml plasma,
respectively (Figure 2C) that trended towards statistical signifi-
cance (P=0.068). The area under the curve (AUC) was used to
calculate the total virus production during viremia. When this was
calculated for each individual animal and was compared between
the species, marmosets had produced more viral RNA, both over
the entire viremic period (1.46109 compared to 6.06107 copies/
ml plasma; Figure 2D), as well as in the first three days of infection
(1.06108 compared to 2.06107 copies/ml plasma; Figure 2E).
Although higher virus production was measured in common
marmosets compared to rhesus macaques, statistical significance
was not reached, likely due to the small group sizes.
Because viral RNA detection using qRT-PCR does not
differentiate between replicating-competent and defective viruses,
we performed virus isolation on plasma samples taken at 0, 2, 6,
and 14 days post-infection from the marmosets and macaques of
the 14-days infection experiment. In plasma collected at day 2 p.i.,
which is at the peak of viral RNA production, marmosets M08009
and M08082 presented a plasma virus titer of 3249 and 2378
TCID50/ml, respectively, while the infectious virus titers in
macaques R01034 and R05066 were 354 and 119 TCID50/ml,
respectively. Thus, in both species 2–3 log more viral RNA was
detected using qRT-PCR than infectious virus particle titers
measured by titration on Vero cells. Virus isolation from all other
time-points was negative.
In humans, WNV was detected in urine for as long as one
month post-infection [45], although this finding remains some-
what controversial [46,47]. To assess if WNV could be detected in
urine from monkeys shortly after infection, RT-PCR was
performed on RNA isolated from pooled urine samples from the
macaques. No evidence was found that WNV was secreted in
urine of the macaques (data not shown).
Absence of WNV-induced clinical signs in rhesus
macaques and common marmosets
In both studies, none of the animals showed any behavioral
changes indicative for neurological illness. Additionally, no
increase of body temperature was observed in any of the animals.
Only normal variations in body temperature, due to circadian
rhythm and/or sedation, were recorded by the data loggers
(Figures 2A and B; yellow lines) or were measured with a
conventional thermometer.
Biochemistry and hematological parameters after WNV
infection
Biochemistry and hematology data were collected from the
animals at days 0, 4, 6, 8 and at the time-point of euthanasia
(Supplementary figures S1 and S2).
As impaired kidney function after WNV infection has been
described in humans, the transient increase of urea and alkaline
phosphatase levels that was observed in plasma of the common
marmosets is interesting. However, as creatinine levels were
normal and albumin levels were stable, these findings most likely
do not reflect significant or sustained renal injury due to WNV
infection. Furthermore, as in macaques a temporary increase of
the liver enzyme ALT, in combination with a transient increase of
alkaline phosphatase and LDH was observed, it rather suggests a
transient and mild congestion of the bile ducts. Some minor
changes were observed in the hematological parameters in some of
the individual animals, but no statistical difference was observed
and values remained within normal variation seen in rhesus
macaques. In the smaller marmosets, hematocrit showed a
statistical significant deviation from the baseline value that is most
likely the result of the frequent blood withdrawal during the study.
Humoral immune response after WNV infection
We analyzed sequential plasma samples from the rhesus
macaques R01034 and R05066 (14-days infection experiment)
for the presence of an anti-WNV E-protein antibody response
[48]. Anti-WNV IgM was first detected 9 days post-infection with
WNV-Ita09, and titers further increased at days 12 and 14 after
challenge (Figure 3). Anti-WNV IgG was detectable at 10 days
post-infection, and similar to IgM, IgG levels increased over time.
Limited blood sampling from marmosets allowed the determina-
tion of antibody levels only at the start of the study and at the time
point of euthanasia at day 14. At the start of the study the
marmosets were negative for E-antigen-specific IgM and IgG, but
both isotypes were clearly detectable at the time point of
euthanasia (Figure 3).
Natural killer cell activation after WNV infection
Because it is still unclear what lymphocyte population is
influenced during the first phase of WNV infection, flow
cytometric analysis was performed at defined time points. Not
only lymphocyte subset compositions were determined, but also T-
cell subsets were defined for the expression of proliferation,
differentiation, and activation markers. In addition, natural killer
(NK) cell, B-cell and dendritic cell subsets were characterized.
T-cells were characterized as CD3+ lymphocytes and according
to the expression of CD4 and CD8 divided into different subsets
(Supplementary figure S3). The markers CD28, CD95, CCR7,
CD27CD45RA were then used to determine the activation and
differentiation status of the T-cell subsets into naive (CD28+
CD952), central memory (CM; CD28+ CD95+ CCR7+, CD27+),
transitional memory (TM; CD28+ CD95+ CCR7+, CD272),
effector memory (EM; CD282, CD45RA2), and effector cells
WNV Infection in Rhesus and Marmosets
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(CD282, CD45RA+). No evidence was found for changes in these
T-cell subsets due to WNV infection in any of the animals
(Supplementary figure S4).
Next, the B-cells were analyzed. Due to lack of cross-reactivity
between some of the antibodies and marmoset lymphocytes, this
analysis was only performed on PBMC from rhesus macaques. Cells
positive for CD19 and HLA-DR were selected from the lymphogate
and divided into three major subsets, CD10+, CD102 and IgG+ B-
cells. CD102 B-cells were further subdivided into plasmablasts
(CD27highCD212), activated memory B-cells (CD27dimCD212),
tissue B-cells (CD27lowCD212), naive B-cells (CD27lowCD21+), and
memory B-cells (CD27lowCD21+) (Supplementary figure S5). In
none of the monkeys we observed a clear effect ofWNV infection on
B-cell subsets during the first 14 days of infection.
Figure 2. Viral kinetics and body temperature. Viral kinetics and body temperature of animals during (A) 14-days follow-up, and (B) 3-days
follow-up. Dark blue areas represent the quantification of the WNV RNA load (RNA copies per ml, plotted on the left y-axis). The yellow lines represent
the body temperature (in uC on the right Y-axis). Both parameters are plotted against time in days (x-axis). Due to technical failure of the temperature
registration software only the body temperature registration of R01034 could be retrieved from the data logger. (C) Peak virus load was calculated for
rhesus macaques and compared with the peak virus load of marmosets. (D) Total virus production in rhesus macaques and marmosets from the 14-
days infection study calculated from the area under the curve (AUC). (E) Total virus production in rhesus macaques and marmosets from the 3-days
infection study calculated from the AUC.
doi:10.1371/journal.pntd.0002797.g002
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For the same reason as mentioned above, only the dendritic
cells (DC) of the macaques were analyzed. CD32HLA-
DR+CD202 cells within the lymphogate were analyzed for
expression of CD14. CD14+ were defined as monocytes, while
the CD142 cells were further subdivided into B-cells (CD20+),
CD1c+ myeloid DC (mDC; CD1232CD1c+), CD11c+ mDC
(CD1232CD11c+) and plasmacytoid DC (pDC;
CD123+CD11c2). No deviations were observed as an effect of
WNV infection in rhesus macaques during the first 14 days
(Supplementary figure S6).
Because innate immunity, and especially natural killer (NK)
cells, plays an important role against WNV infection [49–51], we
also characterized different NK-cell subsets during the first 14 days
of WNV infection. CD32CD45+ cells were selected for the
absence of CD14 and CD20 surface markers. Based on the
expression of CD16 and CD56 within this population, three
subpopulations could be distinguished: CD56bright, CD16bright and
CD562/CD162 double-negative cells (Figure 4A). A general
increase of CD16bright cells within the NK-cell population was
observed over time in all four monkeys (Figure 4B). This rise in
CD16bright cells was not only detectable in the NK-cell fraction,
but also in the total number of lymphocytes (Figure 4C). The
CD16bright cells were further analyzed for the expression of
CD161, NKG2A and NKp44 surface markers. After WNV
infection, the expression of CD161, NKG2A, and NKp44 on the
CD16bright NK-cells was upregulated (Figure 4D to F). No such
effect was observed in other NK-cell subsets.
WNV distribution in post mortem tissues
Samples from different organs and tissues were collected at
necropsy, and analyzed for the presence of WNV RNA by using a
diagnostic nested RT-PCR assay. From each organ or tissue, at
least 2 pieces of tissue were analyzed in 2 separate tests. In cases
when the PCRs were inconclusive, a third piece of tissue was
analyzed. The PCR data are summarized in Table 1.
Three days after infection more tissues were positive for WNV
RNA in the common marmosets than in the macaques. Seven
samples were WNV-positive in common marmoset M09134, while
in marmoset M09135 nine tissues tested positive. Viral RNA was
found in the axillary and mesenteric lymph nodes, the lung, and
the adrenal gland of both animals. Samples from the tonsil, gall
bladder, trachea, thymus, ileum, stomach, kidney, and urinary
bladder were tested positive in at least one of the marmosets. In
sharp contrast, only one rhesus macaque (R04097) tested positive
in the spleen, while in the other macaque (R04093) no virus was
detected in any of the solid tissue samples. Fourteen days post-
infection the number of WNV-positive tissues was comparable in
both monkey species. West Nile virus RNA was primarily detected
in spleen and lymph node samples from both species. In addition,
viral RNA was found in the urinary bladder of macaque R01034,
and in brain tissues (cerebellum, hippocampus) of macaque
R05066. Marmoset M08009 also tested positive in the hippocam-
pus, and M08082 was positive in one of the kidneys.
Discussion
In this study, we monitored the infection of rhesus macaques
and common marmosets after intradermal inoculation with the
WNV-Ita09 strain over the first 14 days. Both monkey species
tested here were equally susceptible to WNV-Ita09. Common
marmosets, however, showed higher viremia and broader tissue
distribution as compared to rhesus macaques.
Duration of viremia and time-point of the peak in viral RNA
production in the macaques were comparable between the
WNV-Ita09 WNV strain and the earlier described infections
with the NY99 WNV strain [29]. Ratterree et al. reported a
transient and low-level viremia that not exceeded 100
TCID50/ml. In our study macaques show titers of 119 and
354 TCID50/ml, while the titers in marmosets reached 2378
and 3249 TCID50/ml. Whether this is an indication of a
slightly higher pathogenicity of the Ita09 strain is unclear, as a
direct comparison between virus production was not possible
because of the different cell types used to quantitate virus
levels: the monkey kidney Vero cell line versus titration on the
mosquito C6/36 cell line. Using the European strain WNV-
Ita09, IgM and IgG titers were detectable at 9 and 10 days
after infection, respectively, which is earlier as compared to
NY99. WNV-Ita09 induced IgM and IgG with almost similar
kinetics, whereas macaques infected with the NY99 failed to
develop IgG titers before 3 weeks post-infection [29]. In
marmosets, the WNV infection was more pronounced than in
the macaques. In both species, viremia peaked at 2–3 days
after exposure, but marmosets accumulated a higher virus
load, and remained viremic for a longer time period. Despite
Figure 3. Humoral response after WNV infection. WNV-E-protein-
specific IgM and IgG levels of the individual animals during WNV
infection. The antibody binding was calculated as the absorbance at
450 nm minus the absorbance at 520 nm. The mean value of two
independent measurements of 1:50 diluted samples is depicted in the
figure.
doi:10.1371/journal.pntd.0002797.g003
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the high level viremia, none of the animals used in this study
showed any apparent clinical symptoms, which is similar to the
study performed with WNV NY99. This is not entirely
unexpected as the monkeys that were used in both studies
were healthy animals. In humans, severe WNV disease occurs
only in a small percentage of infections, and is often associated
with pre-existing immune disorders [52]. Monkeys with
underlying immune disorders can develop WNV disease as
exemplified by the fatal infection of an aged Barbary macaque
(Macaca sylvanus) in the Toronto Zoo [53]. To study the onset of
WNV disease, but also to investigate vaccination strategies to
be used human target populations, it may be essential to use
immunocompromised monkeys in future experiments. In a
recent publication, Pham et al. [54] used immunocompromised
macaques to examine the pathogenicity of pandemic H1N1
influenza A virus showing the validity of such an approach.
Equally, others have used similar methods to study measles
virus-induced pathogenesis [55,56], or to set up a macaque
model for Epstein-Barr virus pathogenicity in humans [57].
Based on the expression of CD56 and CD16, NK-cells can be
divided into different subsets, where CD56bright cells have
more immune-regulatory properties, while CD16bright cells are
more cytolytic effector cells. Following experimental WNV
infection we observed that CD56dimCD16bright NK-cells were
affected in all examined animals. Though only a limited
number of animals (n = 4) were included in this study, the
increase in this particular NK population was evident. A
higher expression of activating receptors CD161 and NKG2A
on CD56dimCD16bright NK-cells has been associated with an
increased lytic capacity of the NK-cells [58]. Recruitment of
CD56dimCD16bright NK-cells by macaques in reaction to
WNV infection may be a mechanism to control further spread
of the virus. A potential role for NK-cells is consistent with the
decrease in viremia before an apparent role of the adaptive
immune system, either antibodies or T-cells was observed.
However, Yoshida et al. [59] published that CD16 depletion in
Figure 4. Characterization of NK subsets during WNV infection. (A) Representative example of the gating strategy. CD32, CD45+, CD142
cells were selected from the lymphogate. Depending on the expression of CD56 and CD16 NK-cells were divided into three subsets. (B) Full circles
represent the total NK population and from each individual animal the fraction of CD56bright, CD16bright and D16negCD56neg of total NK population is
shown at 4 time points after WNV infection. (C) Percentage of CD16bright NK-cells of total lymphocyte population. (D) CD161 expression on CD16bright
NK-cells. (E) NKG2A expression on CD16bright NK-cells. (F) NKp44 expression on CD16bright NK-cells.
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tamarins, a New World monkey that is closely related to
common marmosets, prior to dengue virus infection had no
effect on virus loads, suggesting that NK-cells play only a
limited role in the defense against primary dengue virus
infection. Similarly, NK-cell depletion in mice had no effect on
WNV pathogenesis [60]. Clearly, further investigation is
required to define the possible antiviral function of NK-cell
subsets in the protective immune response against WNV
infection in monkeys and humans.
WNV tissue distribution at three days post-infection was
different in marmosets and macaques. After intradermal inocu-
lation the virus rapidly spread to several organs in the marmosets
whereas in macaques the viral distribution was limited to blood,
and in one animal to the spleen. Fourteen days after infection
differences in virus distribution between the species had
practically disappeared. The exact cause is unknown; virus dose
used to inoculate the monkeys may have influenced tissue
distribution as marmosets were infected with a higher dose per kg
body weight than macaques. Furthermore, species differences
also may have influenced tissue distribution, similar to WNV
kinetics and production. Pogodina et al. [28] also investigated
tissues from rhesus macaques 2 weeks post-infection., and
cultured WNV from brain and spinal cord (5 out of 8 monkeys),
and from homogenates of internal organs (9% of isolations).
However, all animals from the Pogodina study died of fatal
encephalitis after cerebral inoculation with a different strain of
WNV, which makes a direct comparison between studies not
possible.
In the present study West Nile virus RNA was frequently
detected in primary and secondary lymphoid tissues, including
lymph nodes, tonsils, thymus and spleen. This distribution pattern
implies that these tissues represent sites for virus replication;
although detection of virus as part of formed immune complexes
cannot be ruled out. The latter situation may be less conceivable at
Table 1. West Nile virus tissue distribution in infected rhesus macaques and common marmosets.
Day Animal Tissue1 Sample 1 Sample 2 Sample 3
3 R04097 Spleen 2 + ND
3 M09134 Ax LN 2 + no tissue left
Mes LN 2 + no tissue left
Lung 2 2 +
Adrenal gland + + ND
Tonsil + + ND
Gall bladder + + ND
Trachea + + ND
3 M09135 Ax LN + + ND
Mes LN 2 + no tissue left
Lung + 2 2
Adrenal gland + + ND
Thymus + 2 +
Ileum + + 2
Stomach + + ND
Kidney R + 2 +
Urinary bladder + 2 2
14 R01034 Spleen + + ND
Ax LN + + ND
Ing LN + 2 +
Urinary bladder + 2 2
14 R05066 Spleen + + ND
Ax LN + + ND
Cerebellum + 2 2
Hippocampus 2 + 2
14 M08009 Ax LN + + +
Ing LN + 2 +
Mes LN + 2 +
Hippocampus + 2 2
14 M08082 Spleen + 2 2
Ax LN 2 + no tissue left
Ing LN + ND no tissue left
Kidney R + 2 2
1For abbreviations see methods section.
doi:10.1371/journal.pntd.0002797.t001
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3 days post-infection when no anti-WNV antibodies were
detectable, but immune-complexes may have been formed 2
weeks after infection when antibodies were readily found in serum.
West Nile virus can cause serious neurological disorders in
humans, and the infection of brain tissues, like the hippocampus
(R05066 and M08009) and the cerebellum (R05066), is thus of
interest. Beyond this, organs from the endocrine system, like
the adrenal gland, the pancreas, and the stomach were also
found positive for WNV. The virus has also been documented
by others in monkey brain tissues including cerebral cortex,
subcortical ganglia, and cerebellum of persistently-infected
macaques, irrespective of disease, in addition to kidneys,
spleen, and lymph nodes [28]. The combined findings in
monkeys resemble WNV distribution in humans as was
described in the study of post mortem tissues of six patients
that died of WNV infection [52]. The presence of WNV in
kidneys of macaques and marmosets is interesting because in
humans WNV RNA reportedly is excreted in urine during
acute infection [45,61,62], although this finding is not fully
accepted [46,47,63]. Here, we were unsuccessful in retrieving
WNV RNA from urine samples from macaques, but we did
detect WNV RNA in kidney tissue from common marmosets.
We did however detect WNV RNA in urinary bladder
samples from two animals. This is an interesting finding since
the origin of excreted WNV in urine is unknown and resident
kidney cells do not seem permissive for WNV replication [64].
Experiments are ongoing to confirm these findings using
immunohistochemistry.
Until now, rhesus macaques and baboons have been the
only non-human primate models to study WNV infection and
to evaluate potential vaccine candidates. However, research
with both species is expensive because of specialized housing
and care, and can require large amounts of test compounds
because of the size of the animals. A smaller non-human
primate model to study WNV infection is therefore desirable.
We found that the common marmoset is at least equivalently if
not more susceptible to infection with WNV than macaques,
and thus may be a valuable asset to WNV research, due to its
smaller size and comparable immune response to other
primates and humans.
Supporting Information
Figure S1 Serum chemistry data. Changes in biochemistry
parameters of the individual rhesus macaques (red and blue
lines) and common marmosets (orange and green lines) during
the 14-days follow-up period. Day 0 indicates the day of WNV
infection. The mean value of the two rhesus macaques
measured at time point x was compared with the mean value
of the two rhesus macaques at time point 0 using a 2-way
ANOVA test. Statistical difference was defined as p,0.05
(represented by * for rhesus macaques). Same method was used
to calculate statistical difference in common marmoset samples
and this is represented by the # in graphs.
(TIF)
Figure S2 Hematology data. Changes in hematology
parameters during the 14-days follow-up period of the in
individual rhesus macaques (red and blue lines) and common
marmosets (orange and green lines). Day 0 indicates the day of
WNV infection. The mean value of the two rhesus macaques
measured at time point x was compared with the mean value of
the two rhesus macaques at time point 0 using a 2-way
ANOVA test. Statistical difference was defined as p,0.05
(represented by * for rhesus macaques). Same method was used
to calculate statistical difference in common marmoset samples
and this is represented by the # in graphs.
(TIF)
Figure S3 Proliferative T-cells in PBMC after WNV
infection. (A) A representative example of the gating strategy.
Cells in the lymphogate were selected based on the expression of
CD3. CD3+ cells were divided into CD4+, CD8+, or CD4+CD8+
double-expressing T-cells. Next, Ki67 expression was determined
as a measure for the proliferative properties of the different T-cell
populations. (B) Full circle represents the total T-cell fraction per
animal per time-point. Within this fraction the CD4+ (blue), CD8+
(grey), and CD4+CD8+ (red) T-cells are indicated. The exploded
slices from the pie represent the share of proliferating cells per
subtype.
(TIFF)
Figure S4 T-cell differentiation during WNV infection.
(A) Representative example of the gating strategy. CD3
positive cells within the lymphogate were divided into three
different populations based on the expression of CD4 and
CD8. CD4 T-cells, CD8 T-cells, and double-positive T-cells
were divided into naive (CD28+CD952), memory
(CD28+CD95+), and effector cells (CD282). Next, based on
the expression of CCR7 and CD27, memory cells were divided
into central memory (CM) (CCR7+CD27+) and transitional
memory (TM) (CCR72CD27+) cells. Effector cells were
analyzed for the expression of CD45RA, and split into effector
memory cells (EM: CD45RA2) and effector cells (CD45RA+).
(B) Pie diagrams of the differentiation status of CD4+, CD8+,
and double-positive T-cells. Full circles represent the total
CD4+, CD8+, or CD4+CD8+ T-cell populations in each animal
at different time-points post-infection.
(TIFF)
Figure S5 B-cell subsets during WNV infection in
macaques. (A) Representative example of the gating strategy.
CD19+HLA-DR+ cells were divided into CD10+ and CD102
cells. Next, based on the expression of CD27 and CD21, CD10
negative B-cells were divided into plasmablasts, memory B-
cells, naive B-cells, activated memory B-cells, and tissue
memory B-cells. The percentage of IgG-producing the total
number of B-cells was analyzed. (B) The full circles represent
the total number of B-cells of the individual animals at
different time points while the pie parts represent different B-
cell subsets.
(TIFF)
Figure S6 Dendritic cell subsets during WNV infection
in rhesus macaques. (A) Representative example of the
gating strategy for the determination of the different DC
subsets. CD32, CD82, HLA-DR+ cells were selected from the
lymphogate. Cells negative for CD20 were analyzed for the
expression of CD14. CD14+ cells were defined as activated
monocytes while CD142 cells were divided into CD1c mDC
(CD1232CD1+), pDC (CD123+CD112) and CD11c mDC
(CD1232CD11+). (B) The full circles represent the total
number of CD32HLA-DR+D202 dendritic cells while the
pie parts represent the different DC subsets at the different
time points.
(TIFF)
Table S1 FACS antibodies used in study. List of antibodies
used to assess changes in lymphocyte subset composition during
WNV infection.
(DOCX)
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